Patient Characteristics
| Efficacy cohort | |||
|---|---|---|---|
| Characteristic | All patients (n = 532) | Composite cohort (n = 162) | Histopathologic cohort (n = 22) |
| Median age (y) | 71 (range, 48–89) | 71 (range, 51–90) | 68 (range, 56–82) |
| PCa therapy | |||
| Local salvage therapy | 121 (23) | 29 (18) | 7 (32) |
| Androgen deprivation therapy | 58 (11) | 27 (17) | 0 (0) |
| Multiple treatment | 115 (22) | 53 (33) | 8 (36) |
| Others | 2 (0) | 2 (1) | 0 (0) |
| Not available/no prior treatment | 236 (44) | 51 (31) | 7 (32) |
| Time between surgery and PSMA PET (y) | |||
| Median | 4.7 (range, 0–28) | 4.0 (range, 0–23) | 3 (range, 1–23) |
| <4.7 | 264 (50) | 86 (53) | 12 (55) |
| ≥4.7 | 267 (50) | 74 (46) | 9 (41) |
| Not available | 1 (0) | 2 (1) | 1 (5) |
| Primary T stage | |||
| ≤T2 | 152 (29) | 41 (25) | 11 (50) |
| ≥T3 | 288 (54) | 99 (61) | 7 (32) |
| Not available | 92 (17) | 22 (14) | 4 (18) |
| Pathologic regional LN staging (pN) | |||
| pN0 | 296 (56) | 86 (53) | 11 (50) |
| pN1 | 118 (22) | 46 (28) | 6 (27) |
| pNx | 118 (22) | 30 (19) | 5 (23) |
| Gleason score/ISUP–grade group | |||
| ≤7/≤3 | 155 (29) | 56 (35) | 11 (50) |
| ≥8/≥4 | 116 (22) | 46 (28) | 8 (36) |
| Not available | 261 (49) | 60 (37) | 3 (14) |
| PSA nadir after prostatectomy (ng/mL)* | |||
| Median | 0.1 (range, 0–200) | 0.01 (range, 0–19) | 1.19 (range, 0–132) |
| <0.1 | 135 (25) | 12 (7) | 3 (14) |
| ≥0.1 | 86 (16) | 8 (5) | 0 (0) |
| Not available | 311 (58) | 142 (88) | 19 (86) |
| Median PSA at the time of PET/CT (ng/mL) | 0.97 (range, 0–400) | 1.19 (range, 0–132) | 0.84 (range, 0.19–11.6) |
| dtPSA (mo)† | |||
| Median | 6.84 (range, 1–179) | 5.02 (range, 1–33) | 4.06 (range, 1–9) |
| <6.8 | 59 (11) | 27 (17) | 4 (18) |
| ≥6.8 | 62 (12) | 14 (9) | 2 (9) |
| Not available | 411 (77) | 121 (75) | 16 (73) |